BioMarin Pharmaceutical Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Alexander Hardy

Chief Executive Officer (CEO)

US$18.6m

Compensación total

Porcentaje del salario del CEO	0.3%
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	4.3yrs
Promedio de permanencia en la Junta Directiva	7.8yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Alexander Hardy en comparación con los beneficios de BioMarin Pharmaceutical?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	US$205m
Dec 31 2023	US$19m	US$65k	US$168m

Compensación vs. Mercado: La compensación total de Alexander($USD18.59M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD5.57M).

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Alexander con los resultados de la empresa.

CEO

Alexander Hardy (54 yo)

less than a year

Permanencia

US$18,586,001

Compensación

Mr. Alexander Hardy serves as President, Chief Executive Officer & Director of BioMarin Pharmaceutical Inc. since December 01, 2023. He had been Chief Executive Officer at Genentech, Inc. since March 1, 20...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Alexander Hardy	President	less than a year	US$18.59m	sin datos
Brian Mueller	CFO & Executive VP	4.3yrs	US$4.85m	0.023% $ 3.3m
C. Guyer	Executive VP & Chief Technical Officer	no data	US$5.70m	0.017% $ 2.5m
Jeffrey Ajer	Executive VP & Chief Commercial Officer	11.6yrs	US$5.07m	0.028% $ 4.1m
Henry Fuchs	President of Worldwide Research & Development	7.6yrs	US$9.66m	0.058% $ 8.5m
Erin Burkhart	Group VP & Chief Accounting Officer	2yrs	sin datos	0.00014% $ 20.3k
Kevin Eggan	Chief Scientific Officer & Senior VP of Research and Early Development	no data	sin datos	sin datos
Traci McCarty	Group Vice President of Investor Relations	no data	sin datos	sin datos
George Davis	Executive VP	20.3yrs	US$5.19m	0.029% $ 4.3m
Humaira Serajuddin	Senior VP & Chief Marketing Officer	2yrs	sin datos	sin datos
Amy Wireman	Executive VP & Chief People Officer	5.3yrs	sin datos	sin datos
Brinda Balakrishnan	Executive VP	2.3yrs	sin datos	sin datos

4.3yrs

Permanencia media

53yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de BM8 se considera experimentado (4.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Alexander Hardy	President	less than a year	US$18.59m	sin datos
Richard Meier	Independent Chairman of the Board	17.4yrs	US$515.44k	0.059% $ 8.5m
Jean-Jacques Bienaime	Director	no data	US$22.11m	0.35% $ 50.7m
David E. Pyott	Independent Director	8.3yrs	US$470.44k	0.022% $ 3.1m
Elaine Heron	Independent Director	21.8yrs	US$486.44k	0.046% $ 6.7m
V. Lawlis	Independent Director	16.9yrs	US$470.44k	0.015% $ 2.2m
Willard Dere	Independent Director	7.8yrs	US$480.44k	0.012% $ 1.8m
Maykin Ho	Independent Director	3.3yrs	US$473.94k	0.0066% $ 949.8k
Dennis Slamon	Independent Director	10.2yrs	US$460.44k	0.014% $ 2.1m
Robert Hombach	Independent Director	6.7yrs	US$486.94k	0.014% $ 2.0m
Mark J. Alles	Independent Director	2.3yrs	US$483.94k	0.0057% $ 831.1k
Elizabeth Anderson	Independent Director	4.8yrs	US$480.44k	0.010% $ 1.4m

7.8yrs

Permanencia media

69.5yo

Promedio de edad

Junta con experiencia: La junta directiva de BM8 se considera experimentada (7.8 años de antigüedad promedio).

BioMarin Pharmaceutical Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

BioMarin Pharmaceutical Inc., Annual General Meeting, May 21, 2024

Insider recently sold €2.8m worth of stock

Biomarin Announces Board Changes, Effective May 20, 2024

Biomarin Pharmaceutical Inc. Announces Resignation of Jeffrey Ajer as Executive Vice President and Chief Commercial Officer, Effective from July 1, 2024

BioMarin Pharmaceutical Inc. Announces Board Appointments, Effective December 27, 2023

Biomarin Pharmaceutical Inc. Announces CEO Changes

Recent updates

Biomarin Pharmaceutical Inc. Announces Positive New Data Supporting the Safety and Efficacy of VOXZOGO® (Vosoritide) in Children

First quarter 2024 earnings released: EPS: US$0.47 (vs US$0.27 in 1Q 2023)

BioMarin Pharmaceutical Inc., Annual General Meeting, May 21, 2024

Insider recently sold €2.8m worth of stock

Biomarin Announces Board Changes, Effective May 20, 2024

Full year 2023 earnings released: EPS: US$0.89 (vs US$0.76 in FY 2022)

BioMarin Pharmaceutical Inc. Provides Earnings Guidance for the Year 2024

Biomarin Pharmaceutical Inc. Announces Resignation of Jeffrey Ajer as Executive Vice President and Chief Commercial Officer, Effective from July 1, 2024

BioMarin Pharmaceutical Inc. Announces Board Appointments, Effective December 27, 2023

Biomarin Pharmaceutical Inc. Announces CEO Changes

Biomarin Pharmaceutical Inc. Announces CEO Changes

Third quarter 2023 earnings released: EPS: US$0.21 (vs US$0.036 loss in 3Q 2022)

BioMarin Pharmaceutical Inc. Revises Financial Guidance for the Full Year 2023

U.S. Food and Drug Administration Approves Biomarin's Voxzogo® (Vosoritide) for Children Under 5 Years with Achondroplasia

Biomarin Pharmaceutical Inc. to Present Data Showing Long-Term Benefit of Vosoritide on Growth in Children with Achondroplasia At 2023 European Society for Paediatric Endocrinology Meeting

BioMarin Pharmaceutical Inc. Announces First Person Treated with ROCTAVIAN (Valoctocogene Rxaparvovec-Rvox) for Severe Hemophilia A in Europe

Executive VP recently sold €899k worth of stock

Second quarter 2023 earnings released: EPS: US$0.30 (vs US$0.15 in 2Q 2022)

Biomarin Pharmaceutical Inc. Updates Earnings Guidance for the Year Ended December 31, 2023

Bernstein Litowitz Berger & Grossmann LLP Announces Pendency of Class Action and Proposed Settlement for Purchasers of Biomarin Pharmaceutical Inc

U.S. Food and Drug Administration Approves Biomarin's Roctavian® (Valoctocogene Rxaparvovec-Rvox) Gene Therapy for Adults with Severe Hemophilia A

BioMarin Pharmaceutical Inc. to Present Roctavian™ Data from Longest and Largest Hemophilia Gene Therapy Clinical Trial Program

First quarter 2023 earnings released: EPS: US$0.27 (vs US$0.66 in 1Q 2022)

Full year 2022 earnings released: EPS: US$0.76 (vs US$0.35 loss in FY 2021)

BioMarin Pharmaceutical Inc. to Report Q4, 2022 Results on Feb 27, 2023

Biomarin Pharmaceutical Inc. Announces Stable and Durable Annualized Bleed Control for Roctavian(Tm) in Large Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A; 134-Participant Study Met All Primary and Secondary Efficacy Endpoints At 3-Year Analysis

BioMarin Pharmaceutical Inc. Announces That the European Medicines Agency Validated Its Type II Variation Application to Extend the Indication for VOXZOGO® (Vosoritide) for Injection to Treat Children with Achondroplasia Under the Age of 2

BioMarin Pharmaceutical Inc. Announces Advancements in FDA Review of ROCTAVIAN™ (Valoctocogene Roxaparvovec) for Adults with Severe Hemophilia A

BioMarin Pharmaceutical Inc. Announces Incremental Progress on Biologics License Application (BLA) Review for Valoctocogene Roxaparvovec AAV Gene Therapy for Adults with Severe Hemophilia A Program

BioMarin Pharmaceutical Inc. Reaffirms Earnings Guidance for the Year 2022

FDA Accepts Biomarin's Biologics License Application (Bla) for Valoctocogene Roxaparvovec Aav Gene Therapy for Adults with Severe Hemophilia A

BioMarin Pharmaceutical Inc. to Report Q3, 2022 Results on Oct 26, 2022

BioMarin Pharmaceutical Inc. Announces First Gene Therapy for Adults with Severe Hemophilia A, BioMarin's ROCTAVIAN(TM) (valoctocogene roxaparvovec), Approved by European Commission (EC)

Insider recently sold €586k worth of stock

Second quarter 2022 earnings released: EPS: US$0.15 (vs US$0.071 in 2Q 2021)

Biomarin Pharmaceutical Inc. Revises Earnings Guidance for the Full Year 2022

BioMarin Pharmaceutical Inc. Receives Positive CHMP Opinion in Europe for Valoctocogene Roxaparvovec Gene Therapy to Treat Adults with Severe Hemophilia A

BioMarin Announces the Ministry of Health, Labor and Welfare (MHLW) in Japan Granted Approval for VOXZOGO (vosoritide) for Injection for the Treatment of Children with Achondroplasia, Whose Growth Plates are Not Closed

BioMarin Pharmaceutical Inc. Announces Favorable Results from Global Phase 2 Study of Voxzogo™ (Vosoritide) for Injection in Infants and Young Children with Achondroplasia At the Endocrine Society Annual Meeting

BioMarin Pharmaceutical Inc. Announces Durable Hemostatic Efficacy Maintained over 6 Years in Ongoing Phase 1 2 Study of Valoctocogene Roxaparvovec

BioMarin Pharmaceutical Inc. Announces Executive Appointments

First quarter 2022 earnings released: EPS: US$0.66 (vs US$0.096 in 1Q 2021)

BioMarin Pharmaceutical Inc. Provides Earnings Guidance for the Full Year 2022

BioMarin Pharmaceutical Inc., Annual General Meeting, May 24, 2022

Independent Director recently sold €446k worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

BioMarin Pharmaceutical Inc. Provides Earnings Guidance for the Full Year of 2022

BioMarin Pharmaceutical Inc. Provides Updates on Progress in Gene Therapy Programs

BioMarin Pharmaceutical Inc. Announces Stable and Durable Annualized Bleed Control in the Large Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A; 134-Participant Study Met All Primary and Secondary Efficacy Endpoints At Two Year Analysis

ROSEN, A LEADING LAW FIRM, Encourages BioMarin Pharmaceutical Inc. Investors to Secure Counsel Before Important December 22 Deadline in Securities Class Action

Chairman & CEO recently sold €116k worth of stock

Third quarter 2021 earnings released: US$0.20 loss per share (vs US$4.33 profit in 3Q 2020)

Second quarter 2021 earnings released: EPS US$0.14 (vs US$0.16 loss in 2Q 2020)

BioMarin Announces Oral Presentation of Positive One-Year Results from Phase 3 Pivotal Trial with Valoctocogene Roxaparvovec Gene Therapy in Adults with Severe Hemophilia at International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress

European Medicines Agency Validates Biomarin's Marketing Authorization Application for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A

BioMarin Pharmaceutical Inc.(NasdaqGS:BMRN) dropped from Russell Midcap Growth Index

BioMarin Pharmaceutical Inc. Receives Positive CHMP Opinion in Europe for Vosoritide for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close

Independent Director Michael Grey has left the company

European Medicines Agency Grants BioMarin Pharmaceutical Inc.'s Request for Accelerated Assessment of Valoctocogene Roxaparvovec for Treatment of Severe Hemophilia A

BioMarin Provides Highlights of 5 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec with the Longest Duration of Clinical Experience for a Gene Therapy in Hemophilia A

BioMarin Pharmaceutical Inc. Announces 6 Presentations at American Society of Gene and Cell Therapy (ASGCT) Virtual 2021 Annual Meeting

First quarter 2021 earnings released: EPS US$0.096 (vs US$0.45 in 1Q 2020)

Biomarin Pharmaceutical Inc. Reaffirms Earnings Guidance for the Full Year of 2021

BioMarin Pharmaceutical Inc. Announces Data from the Open-Label Long-Term Extension of the Phase 3 Study

BioMarin Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Valoctocogene Roxaparvovec, Investigational Gene Therapy for Hemophilia A

New 90-day low: €62.88

BioMarin Pharmaceutical Inc. Completes Full Enrollment in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia

Full year 2020 earnings released: EPS US$4.75 (vs US$0.13 loss in FY 2019)

Revenue beats expectations